Darolutamide tablets, for the treatment of adult patients with high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC).
This Chinese-language instruction leaflet covers NUBEQA (darolutamide) 300 mg film-coated tablets. It states that darolutamide is indicated for adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.
The leaflet describes the tablet composition and appearance, the recommended dose of 600 mg twice daily with food, dose adjustments for severe renal or moderate hepatic impairment, adverse reactions from the ARAMIS study, contraindications, warnings, drug interactions, and pregnancy/lactation precautions. This manual is written in Chinese.
| Strength | 300 mg |
|---|---|
| Recommended dosage | 600 mg twice daily, orally |
| Total daily dose | 1200 mg |
| Molecular formula | C19H19ClN6O2 |
| Molecular weight | 398.85 |
| Appearance | White or off-white oval film-coated tablets |
| Tablet imprint | 300 on one side; BAYER on the other |
It is indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis.
The recommended dose is 600 mg (two 300 mg film-coated tablets) taken orally twice daily, for a total daily dose of 1200 mg.
Take it as soon as remembered before the next scheduled dose; do not take two doses at the same time to make up for a missed dose.
For severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2), the recommended starting dose is 300 mg twice daily.